儿科亚托邦性皮肤炎护理的创新:检查新兴的局部治疗选择
Christina McGee1, Alexander J Jafari2, Adelaide A Hebert2,3,4
1UTHealth McGovern Medical School, Houston, TX, USA.
Expert review of clinical pharmacology
|March 11, 2026
概括
新的局部治疗为儿科亚托皮性皮肤炎 (AD) 提供了类固醇节约的选择. 新兴药物表现有前途,但长期的安全性和有效性数据对于优化治疗这种慢性皮肤疾病的儿童至关重要.
科学领域:
- 皮肤病学 皮肤病学
- 儿科过敏和免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎 (AD) 是儿童的一种慢性炎症性皮肤病,表现为和病变.
- 它的发展涉及皮肤屏障问题,免疫反应,遗传和环境因素.
- 儿科阿尔茨海默症往往与过敏同时发生,并对儿童和家庭产生重大影响.
研究的目的:
- 审查近期针对儿科亚托邦性皮肤炎的局部类固醇节约疗法的进展.
- 突出新兴和正在研究的治疗方法来管理儿童的这种情况.
主要方法:
- 在PubMed和Clinicaltrials.gov的文献搜索中,查找2025年11月为止的儿科AD局部治疗方法.
- 专注于新型药物及其作用机制作为类固醇节约替代品.
主要成果:
- 目前的第一线治疗方法 (皮质类固醇,氨酸抑制剂,克里萨博罗尔) 在安全性和长期使用方面存在局限性.
- 新型局部药物,如罗夫卢米拉斯特,鲁克索利提尼布和塔皮纳罗夫,提供了不同的机制.
- 这些新兴疗法扩大了传统治疗方法之外的治疗选择.
结论:
- 新兴的局部疗法对儿科阿尔茨海默病有很大的潜力,解决尚未满足的需求.
- 进一步研究长期的安全性和现实世界的有效性对于临床优化至关重要.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K
Pharmacokinetics in Pediatric Patients: Drug Excretion
349
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
349
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
622
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
622
Skin Cancer
6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K
Clinical Applications of Epidermal Stem Cells
3.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.4K
Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884


